Lung Cancer Dispatch
Follow
Find tag "siRNA"
4.2K views | +1 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in
Patients with Solid Tumors and Hematological Malignancies

Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in <br/>      Patients with Solid Tumors and Hematological Malignancies | Lung Cancer Dispatch | Scoop.it

"Dicerna Pharmaceuticals, Inc. DRNA +0.67% , a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC, Dicerna’s first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma."


Editor's note: This new drug may hold promise for people with lung cancer or melanoma, as well as other cancer types.

Cancer Commons's insight:

MarketWatch  |  Apr 16, 2014

more...
Cancer Commons's curator insight, April 18, 2014 2:29 PM

MarketWatch  |  Apr 16, 2014

Suggested by Cancer Commons
Scoop.it!

Inhalable Chemotherapy May Offer Superior Lung Cancer Treatment

Inhalable Chemotherapy May Offer Superior Lung Cancer Treatment | Lung Cancer Dispatch | Scoop.it

A new drug delivery system attaches chemotherapy drugs to nanocarriers–microscopically tiny particles–to create an inhalable lung cancer treatment. Because this approach delivers drugs directly into the lung, it minimizes their effects on the rest of the body, potentially reducing side effects. The drugs also reach the lungs in their most potent form, without being degraded after injection into the bloodstream during transport to the lung. In addition to chemotherapy, the nanocarriers can also deliver another type of small particle, called siRNA, designed to combat drug resistance. In a recent study, this inhalable combination treatment drastically shrank lung cancer tumors implanted in mice, and resulted in 83% of the drug being delivered to the lung, compared to 23% when the drug was injected. However, further testing is necessary before this treatment can be investigated in human clinical trials.

Cancer Commons's insight:

ScienceDaily | May 22, 2013

more...
No comment yet.